Jean-Tristan Brandenburg1, Melanie A Govender2,3, Cheryl A Winkler4, Palwende Romuald Boua2,5, Godfred Agongo6,7, June Fabian8,9, Michèle Ramsay1,3. 1. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa jean-tristan.brandenburg@wits.ac.za michele.ramsay@wits.ac.za. 2. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. Molecular Genetic Epidemiology Section, Basic Research Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland. 5. Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé-DRCO, Nanoro, Burkina Faso. 6. Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana. 7. Department of Biochemistry and Forensic Sciences, School of Chemical and Biochemical Sciences, C.K. Tedam University of Technology and Applied Sciences, Navrongo, Ghana. 8. Wits Donald Gordon Medical Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 9. Medical Research Council/Wits University Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
BACKGROUND AND OBJECTIVES: Recessive inheritance of African-specific APOL1 kidney risk variants is associated with higher risk of nondiabetic kidney disease, progression to kidney failure, and early-onset albuminuria that precedes eGFR decline. The effect of APOL1 risk variants on kidney disease in continental Africans is understudied. Objectives of this study were to determine APOL1 risk allele prevalence and associations between APOL1 genotypes and kidney disease in West, East, and South Africa. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This cross-sectional population-based study in four African countries included 10,769 participants largely aged 40-60 years with sociodemographic and health information, anthropometry data, and blood and urine tests for biomarkers of kidney disease. APOL1 risk alleles were imputed from the H3Africa genotyping array, APOL1 risk allele and genotype frequencies were determined, and genetic associations were assessed for kidney disease. Kidney disease was defined as the presence of eGFR <60 ml/min per 1.73 m2, albuminuria, or a composite end point including eGFR <60 ml/min per 1.73 m2 and/or albuminuria. RESULTS: High G1 allele frequencies occurred in South and West Africa (approximately 7%-13%). G2 allele frequencies were highest in South Africa (15%-24%), followed by West Africa (9%-12%). Associations between APOL1 risk variants and albuminuria were significant for recessive (odds ratio, 1.63; 95% confidence interval, 1.25 to 2.12) and additive (odds ratio, 1.39; 95% confidence interval, 1.09 to 1.76) models. Associations were stronger for APOL1 G1/G1 genotypes versus G0/G0 (odds ratio, 3.87; 95% confidence interval, 2.16 to 6.93) compared with either G2/G2 (odds ratio, 1.65; 95% confidence interval, 1.09 to 2.51) or G1/G2 (odds ratio, 1.24; 95% confidence interval, 0.83 to 1.87). No association between APOL1 risk variants and eGFR <60 ml/min per 1.73 m2 was observed. CONCLUSIONS: APOL1 G1 and G2 alleles and high-risk genotype frequencies differed between and within West and South Africa and were almost absent from East Africa. APOL1 risk variants were associated with albuminuria but not eGFR <60 ml/min per 1.73 m2. There may be differential effects of homozygous G1 and G2 genotypes on albuminuria that require further investigation. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_05_16_CJN14321121.mp3.
BACKGROUND AND OBJECTIVES: Recessive inheritance of African-specific APOL1 kidney risk variants is associated with higher risk of nondiabetic kidney disease, progression to kidney failure, and early-onset albuminuria that precedes eGFR decline. The effect of APOL1 risk variants on kidney disease in continental Africans is understudied. Objectives of this study were to determine APOL1 risk allele prevalence and associations between APOL1 genotypes and kidney disease in West, East, and South Africa. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This cross-sectional population-based study in four African countries included 10,769 participants largely aged 40-60 years with sociodemographic and health information, anthropometry data, and blood and urine tests for biomarkers of kidney disease. APOL1 risk alleles were imputed from the H3Africa genotyping array, APOL1 risk allele and genotype frequencies were determined, and genetic associations were assessed for kidney disease. Kidney disease was defined as the presence of eGFR <60 ml/min per 1.73 m2, albuminuria, or a composite end point including eGFR <60 ml/min per 1.73 m2 and/or albuminuria. RESULTS: High G1 allele frequencies occurred in South and West Africa (approximately 7%-13%). G2 allele frequencies were highest in South Africa (15%-24%), followed by West Africa (9%-12%). Associations between APOL1 risk variants and albuminuria were significant for recessive (odds ratio, 1.63; 95% confidence interval, 1.25 to 2.12) and additive (odds ratio, 1.39; 95% confidence interval, 1.09 to 1.76) models. Associations were stronger for APOL1 G1/G1 genotypes versus G0/G0 (odds ratio, 3.87; 95% confidence interval, 2.16 to 6.93) compared with either G2/G2 (odds ratio, 1.65; 95% confidence interval, 1.09 to 2.51) or G1/G2 (odds ratio, 1.24; 95% confidence interval, 0.83 to 1.87). No association between APOL1 risk variants and eGFR <60 ml/min per 1.73 m2 was observed. CONCLUSIONS: APOL1 G1 and G2 alleles and high-risk genotype frequencies differed between and within West and South Africa and were almost absent from East Africa. APOL1 risk variants were associated with albuminuria but not eGFR <60 ml/min per 1.73 m2. There may be differential effects of homozygous G1 and G2 genotypes on albuminuria that require further investigation. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_05_16_CJN14321121.mp3.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Zahra Kanji; Camille E Powe; Julia B Wenger; Chunmei Huang; Elizabeth Ankers; Dorothy A Sullivan; Gina Collerone; Neil R Powe; Marcello Tonelli; Ishir Bhan; Andrea J Bernhardy; Salvatore Dibartolo; David Friedman; Giulio Genovese; Martin R Pollak; Ravi Thadhani Journal: J Am Soc Nephrol Date: 2011-10-13 Impact factor: 10.121
Authors: W H Linda Kao; Michael J Klag; Lucy A Meoni; David Reich; Yvette Berthier-Schaad; Man Li; Josef Coresh; Nick Patterson; Arti Tandon; Neil R Powe; Nancy E Fink; John H Sadler; Matthew R Weir; Hanna E Abboud; Sharon G Adler; Jasmin Divers; Sudha K Iyengar; Barry I Freedman; Paul L Kimmel; William C Knowler; Orly F Kohn; Kristopher Kramp; David J Leehey; Susanne B Nicholas; Madeleine V Pahl; Jeffrey R Schelling; John R Sedor; Denyse Thornley-Brown; Cheryl A Winkler; Michael W Smith; Rulan S Parekh Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: M Ramsay; N Crowther; E Tambo; G Agongo; V Baloyi; S Dikotope; X Gómez-Olivé; N Jaff; H Sorgho; R Wagner; C Khayeka-Wandabwa; A Choudhury; S Hazelhurst; K Kahn; Z Lombard; F Mukomana; C Soo; H Soodyall; A Wade; S Afolabi; I Agorinya; L Amenga-Etego; S A Ali; J D Bognini; R P Boua; C Debpuur; S Diallo; E Fato; A Kazienga; S Z Konkobo; P M Kouraogo; F Mashinya; L Micklesfield; S Nakanabo-Diallo; B Njamwea; E Nonterah; S Ouedraogo; V Pillay; A M Somande; P Tindana; R Twine; M Alberts; C Kyobutungi; S A Norris; A R Oduro; H Tinto; S Tollman; O Sankoh Journal: Glob Health Epidemiol Genom Date: 2016-11-22
Authors: Ernest K Sumaili; Revital Shemer; Etty Kruzel-Davila; Eric P Cohen; Pierre N Mutantu; Justine B Bukabau; Jean Robert R Makulo; Vieux M Mokoli; Jeannine L Luse; Nestor M Pakasa; Etienne Cavalier; Roger D Wumba; Anat Reiner-Benaim; Geoffrey Boner; Meyer Lifschitz; Nazaire M Nseka; Karl Skorecki; Walter G Wasser Journal: Clin Kidney J Date: 2018-10-09
Authors: Ananyo Choudhury; Shaun Aron; Laura R Botigué; Dhriti Sengupta; Gerrit Botha; Taoufik Bensellak; Gordon Wells; Judit Kumuthini; Daniel Shriner; Yasmina J Fakim; Anisah W Ghoorah; Eileen Dareng; Trust Odia; Oluwadamilare Falola; Ezekiel Adebiyi; Scott Hazelhurst; Gaston Mazandu; Oscar A Nyangiri; Mamana Mbiyavanga; Alia Benkahla; Samar K Kassim; Nicola Mulder; Sally N Adebamowo; Emile R Chimusa; Donna Muzny; Ginger Metcalf; Richard A Gibbs; Charles Rotimi; Michèle Ramsay; Adebowale A Adeyemo; Zané Lombard; Neil A Hanchard Journal: Nature Date: 2020-10-28 Impact factor: 69.504